Annovis Bio, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Maria L. Maccecchini
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 101 Lindenwood Drive Malvern PA United States of America 19312
- IPO Date
- Jan 29, 2020
- CIK
- 0001477845
- Website
- annovisbio.com
- Similar Companies
- Business
- Annovis Bio Inc (NYSE: ANVS), a late-stage clinical drug platform company, develops therapies targeting neurodegeneration by inhibiting the synthesis of multiple neurotoxic proteins including phosphorylated tau, APP/A-beta and alpha-synuclein. The lead product candidate, buntanetap (ANVS401, formerly Posiphen), an oral small-molecule drug, advances in Phase 3 trials for early Alzheimer's disease and Parkinson's disease, demonstrating statistically significant cognitive and motor improvements over placebo and baseline in completed studies involving hundreds of patients; ANVS405 progresses in Phase 2/3 trials for acute neurodegeneration from traumatic brain injury and stroke; and ANVS301 completed Phase 1 for later-stage Alzheimer's and dementia. Incorporated in 2008 as QR Pharma Inc and renamed Annovis Bio in 2019, the company founded by Maria L Maccecchini PhD, operates from headquarters in Malvern Pennsylvania USA with research and clinical activities centered in the United States. Recent developments encompass registered direct offerings raising $6 million in October 2025 by selling 4 million shares at $1.50 each and $3.4 million later that month through 1.67 million shares for working capital to support Phase 3 advancements; positive Phase 3 Parkinson's data showing halted cognitive decline and improved UPDRS scores in patients with over three years diagnosis; Phase 3 Alzheimer's completion in 345 patients with dose-dependent ADAS-Cog11 gains especially in APOE4 carriers; CEO Maria Maccecchini assuming acting CFO duties after the finance VP resignation amid ongoing pivotal 18-month Phase 3 enrollment; and reaffirmed analyst Buy ratings with price targets from $10 to $17 despite extended FDA timelines.
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's Disease
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
Annovis Bio Regains NYSE Listing Compliance
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
Michael Hoffman Acquires 713,800 Shares of Annovis Bio (NYSE:ANVS) Stock
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
Annovis Publishes Historical Review of Buntanetap in The Scientist
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
Annovis to Host Corporate Update Webinar on January 28, 2026